Kyle Connors practices in the life sciences and intellectual property transactions groups at Ropes & Gray, advising clients on a broad range of matters including complex licensing arrangements, collaborations, mergers & acquisitions, commercial agreements, and drug pricing strategies.
Prior to joining the firm, Kyle participated in the Patent and Licensing Clinic, where he worked on patent prosecution and licensing matters for the UVA Licensing and Ventures Group. He also worked as a legal intern in the Office of the General Counsel in the Department of Health and Human Services. As an undergraduate student, Kyle worked as a research assistant at an analytical chemistry laboratory and at a contract manufacturer of clinical trial vaccines and therapies.
Experience
- Represented Pfizer in its
- strategic collaboration with Flagship Pioneering to create a new pipeline of innovative medicines
- Ignite program that partners with select biotech companies aligned with Pfizer’s focus areas
- $11.6 billion acquisition of Biohaven Pharmaceuticals
- $6.7 billion acquisition of Arena Pharmaceuticals
- $25 million collaboration with and investment in CellCentric
- Advises global pharmaceutical companies on drug pricing matters related to the Inflation Reduction Act and the Manufacturer Part D Discount Program
- Represented a global pharmaceutical company in its partnership and patient access agreement with a national provider of retail pharmacy and healthcare services
- Represented uniQure N.V. in its global licensing agreement with Apic Bio worth up to $55 million for a clinical stage gene therapy program to treat amyotrophic lateral sclerosis (ALS)
- Advised a global biopharmaceutical company in a collaboration agreement with a research institute to develop a treatment for a novel viral disease
- Advises on academic licenses, clinical and commercial supply agreements, manufacturing agreements, sponsored research agreements, clinical trial agreements, master services agreements, and material transfer agreements for clients such as Solid Biosciences, Walden Biosciences, and Psivant Therapeutics